Abstract

Long noncoding RNAs (lncRNA) are a novel class of transcripts with no protein coding capacity, but with diverse functions in cancer cell proliferation, apoptosis, and metastasis. The lncRNA PVT1 is 1,716 nt in length and located in the chr8q24.21 region, which also contains the myelocytomatosis (MYC) oncogene. Previous studies demonstrated that MYC promotes PVT1 expression in primary human cancers. However, the expression pattern and potential biologic function of PVT1 in non-small cell lung cancer (NSCLC) is still unclear. Here, we found that PVT1 was upregulated in 105 human NSCLC tissues compared with normal samples. High expression of PVT1 was associated with a higher tumor-node-metastasis stage and tumor size, as well as poorer overall survival. Functional analysis revealed that knockdown of PVT1 inhibited NSCLC cell proliferation and induced apoptosis both in vitro and in vivo RNA immunoprecipitation and chromatin immunoprecipitation assays demonstrated that PVT1 recruits EZH2 to the large tumor suppressor kinase 2 (LATS2) promoter and represses LATS2 transcription. Furthermore, ectopic expression of LATS2 increased apoptosis and repressed lung adenocarcinoma cell proliferation by regulating the Mdm2-p53 pathway. Taken together, our findings indicated that PVT1/EZH2/LATS2 interactions might serve as new target for lung adenocarcinoma diagnosis and therapy. Mol Cancer Ther; 15(5); 1082-94. ©2016 AACR.

Highlights

  • Lung cancer is a predominant cause of cancer-related death worldwide, due to its high morbidity and the lack of effective therapy strategies [1]

  • We analyzed the profiles of Non–small cell lung cancer (NSCLC) patient from Gene Expression Omnibus (GEO) and found that PVT1 was upregulated in NSCLC tissues compared with normal lung tissues

  • To explore whether PVT1 was differently expressed in NSCLC tissues, a total of 105 paired NSCLC tissue samples and adjacent normal counterparts were evaluated for PVT1 expression using qPCR assay

Read more

Summary

Introduction

Lung cancer is a predominant cause of cancer-related death worldwide, due to its high morbidity and the lack of effective therapy strategies [1]. Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [2]. Despite recent advancements in clinical and experimental oncology, the prognosis of NSCLC remains poor, with a 5-year overall survival rate of around 11% [3]. Because NSCLC is a multigene disorder, the biologic processes involved in NSCLC tumorigenesis are complicated. A detailed understanding of the mechanisms and molecular pathways underlying NSCLC development and progression is essential to improve diagnosis, prevention, and treatment of NSCLC patients. Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call